Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.

被引：15
|
作者：
Mayer, Erica L.
Wander, Seth Andrew
Regan, Meredith M.
DeMichele, Angela
Forero-Torres, Andres
Rimawi, Mothaffar F.
Ma, Cynthia X.
Cristofanilli, Massimo
Anders, Carey K.
Bartlett, Cynthia Huang
Winer, Eric P.
Burstein, Harold J.
机构：
[1] Dana Farber Canc Inst, Waban, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Baylor Coll Med, Houston, TX 77030 USA
[6] Washington Univ, Sch Med St Louis, St Louis, MO USA
[7] Northwestern Univ, Robert H Lurie Canc Ctr, Feinberg Sch Med, Chicago, IL USA
[8] Univ N Carolina, Chapel Hill, NC 27515 USA
[9] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS1104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1104
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II trial of palbociclib with fulvestrant in individuals with hormone receptorpositive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor
    Tao, Jessica J.
    Blackford, Amanda L.
    Nunes, Raquel
    Truica, Cristina I.
    Mahosky, Justin
    Jones, Mary Kate
    Leasure, Nick C.
    Cescon, Terrence
    Christou, Antonios
    Werner, Jeanine L.
    Couzi, Rima
    Smith, Karen L.
    Santa-Maria, Cesar Augusto
    Wolff, Antonio C.
    Stearns, Vered
    CANCER RESEARCH, 2023, 83 (05)
  • [32] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER).
    Spring, Laura
    Griffin, Colleen
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth Andrew
    Shin, Jennifer
    Abraham, Elizabeth
    Habin, Karleen
    Patel, Jaymin M.
    Comander, Amy H.
    Mulvey, Therese Marie
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, Erica
    DeMichele, Angela
    Gnant, Michael
    Barry, William
    Pfeiler, Georg
    Metzger, Otto
    Burstein, Harold
    Miller, Kathy
    Rastogi, Priya
    Loibl, Sibylle
    Goulioti, Theodora
    Zardavas, Dimitrios
    Fesl, Christian
    Koehler, Maria
    Huang-Bartlett, Cynthia
    Huang, Xin
    Piccart, Martine
    Winer, Eric
    Wolff, Antonio
    CANCER RESEARCH, 2018, 78 (04)
  • [34] PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, E. L.
    Gnant, M. I.
    DeMichele, A.
    Martin, M.
    Burstein, H.
    Prat, A.
    Rubovszky, G.
    Miller, K. D.
    Pfeiler, G.
    Winer, E. P.
    Zdenkowski, N.
    Anderson, D.
    Nowecki, Z.
    Loibl, S.
    Fohler, H.
    Metzger, O.
    Fumagalli, D.
    Theall, K. Puyana
    Fesl, C.
    Dueck, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1145 - S1145
  • [35] Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2-metastatic breast cancer (MBC): A prospective, real-world study
    Palumbo, R.
    Saltalamacchia, G.
    Quaquarini, E.
    Tagliaferri, B.
    Teragni, C. M.
    Barletta, C.
    Frascaroli, M.
    Biscaldi, E.
    Malovini, A.
    Locati, L. D.
    Sottotetti, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S372 - S372
  • [36] Phase 1/2 dose-escalation and expansion study investigating SAR439859+/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2-metastatic breast cancer.
    Bardia, Aditya
    Linden, Hannah M.
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Celanovic, Marina
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] COMPARING EFFICACYAND TOXICITY IN HR+/HER2-METASTATIC BREAST CANCER PATIENTS TREATED WITH RIBOCICLIB OR PALBOCICLIB IN COMBINATION WITH ENDOCRINE THERAPY: RESULTS FROM A SINGLE CENTER IN MEXICO
    Maliachi Diaz, Andrea
    Garcia Padilla, Daniel Alejandro
    Zilli Hernandez, Stefan
    Arce Salinas, Claudia Haydee
    Flores Diaz, Diana Fabiola
    Matus Santos, Juan Antonio
    Espinosa Fernandez, Jose Rodrigo
    Gonzalez Nunez, Carlos Arturo
    Garcilazo Reyes, Alexandra
    Alvarado Miranda, Alberto
    Lara Medina, Fernando Ulises
    Velazquez Martinez, Areli
    Salinas Agramonte, Luis Andre
    Santamaria Galicia, Julieta
    Cabrera Galeana, Paula Anel
    BREAST, 2023, 71 : S50 - S50
  • [38] Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study
    Mayer, Erica L.
    DeMichele, Angela M.
    Guo, Hao
    Miller, Kathy D.
    Rugo, Hope S.
    Schneider, Bryan
    Waks, Adrienne G.
    Come, Steven E.
    Mulvey, Theresa
    Bartlett, Cynthia Huang
    Koehler, Maria
    Barry, William
    Winer, Eric P.
    Burstein, Harold J.
    CANCER RESEARCH, 2018, 78 (04)
  • [39] Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
    Bardia, Aditya
    Modi, Shanu
    Gregor, Mariana Chavez-Mac
    Kittaneh, Muaiad
    Marino, Alyssa J.
    Matano, Alessandro
    Bhansali, Suraj
    Hewes, Becker
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer
    Mayer, E. L.
    Demichele, A. M.
    Pfeiler, G.
    Barry, W.
    Metzger, O.
    Rastogi, P.
    Symmans, F.
    Burstein, H. J.
    Miller, K.
    Loibl, S.
    Schmatloch, S.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Huang, X.
    Piccart, M.
    Winer, E.
    Gnant, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345